Skip to main content
. Author manuscript; available in PMC: 2022 Mar 15.
Published in final edited form as: Cancer Res. 2021 Jun 18;81(18):4641–4651. doi: 10.1158/0008-5472.CAN-21-1109

Figure 1. Immunologic mechanisms and potential of HER2 targeted mAb therapies.

Figure 1.

A) Diagram illustrating the potential MOAs involved in anti-tumor mAb directed therapies. B) A PET scan demonstrating FDG avid sites of disease in a patient initially diagnosed with metastatic HER2 positive breast cancer who had a complete response, or C) following induction docetaxel combined with trastuzumab and pertuzumab.